Resumen: TEVIMBRA aprobado en EE.UU. para el tratamiento de primera línea del cáncer de esófago escamoso avanzado en combinación con quimioterapia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Should l Buy ?
Source: Businesswire
FDA Approval: BeiGene, Ltd. has received FDA approval for TEVIMBRA® (tislelizumab-jsgr) in combination with platinum-based chemotherapy for first-line treatment of adults with inoperable or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (≥1).
Company Name Change: The company plans to change its name from BeiGene, Ltd. to BeOne Medicines Ltd.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
